Sugi Predict

Sugi Predict / Compounds / SCHEMBL260266

SCHEMBL260266

SCHEMBL260266

O=C1CC[C@H](c2ccc(Cl)c(Cl)c2)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 5/20 0.55
▸ SLC6A4 P31645 5/20 0.55
▸ SLC6A3 Q01959 5/20 0.55
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ CYP3A4 P08684 4/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ MLNR O43193 1/20 0.51
▸ NR1I2 O75469 1/20 0.51
▸ ABCB11 O95342 1/20 0.51
▸ ESR1 P03372 1/20 0.51
▸ CHRM2 P08172 1/20 0.51
▸ CHRM4 P08173 1/20 0.51
▸ ABCB1 P08183 1/20 0.51
▸ ADRB1 P08588 1/20 0.51
▸ HTR1A P08908 1/20 0.51
▸ CHRM5 P08912 1/20 0.51
▸ ADRA2A P08913 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29757859 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL29481032 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL30489007 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL7736643 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL260267 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL6261864 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL30592537 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL260276 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL8277375 0.87 MEN1 (0.42) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL10071834 0.87 MEN1 (0.42) SLC6A2SLC6A4SLC6A3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589777-B1 Use to prepare enantiomerically pure precursor material for sertraline synthesis - \"(4S) tetralone\" or 4-(3,4-dichloro-phenyl)-3,4-dihydro-1(2H)-naphthalenone and for subsequent use in preparation of antidepressant and anorectic agents PFIZER INC. 2003-07-08 — — US claimed
US-5750794-A Process for preparing chiral tetralone PFIZER INC. (US) 1998-05-12 — — US claimed
EP-0724552-B1 PROCESS FOR PREPARING A CHIRAL TETRALONE PFIZER (US) 1997-10-29 — — EP claimed
US-20210046021-A1 TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE SUNOVION PHARMACEUTICALS INC. (US) 2021-02-18 — — US disclosed
US-10702486-B2 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine SUNOVION PHARMACEUTICALS INC. (US) 2020-07-07 — — US disclosed
US-10702486-B2 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine SUNOVION PHARMACEUTICALS INC. (US) 2020-07-07 — — US disclosed
WO-2020025646-A1 AN OMEGA-TRANSAMINASE ENZYME UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK (IE) 2020-02-06 — — WO disclosed
EP-3604507-A1 AN OMEGA-TRANSAMINASE ENZYME University College Cork-National University of Ireland, Cork (IE) 2020-02-05 — — EP disclosed
US-10328036-B2 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine SUNOVION PHARMACEUTICALS INC. (US) 2019-06-25 — — US disclosed
US-10328036-B2 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine SUNOVION PHARMACEUTICALS INC. (US) 2019-06-25 — — US disclosed
US-20180333373-A1 TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE SUNOVION PHARMACEUTICALS INC. (US) 2018-11-22 — — US disclosed
EP-1545485-A2 TREATMENT OF CNS DISORDERS WITH TRANS-4- (3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE Sepracor Inc. (US) 2005-06-29 — — EP disclosed
EP-1542961-A1 TREATMENT OF CNS DISORDERS WITH TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE AND ITS FORMAMIDE Sepracor, Inc. (US) 2005-06-22 — — EP disclosed
US-20040092605-A1 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide SEPRACOR, INC. 2004-05-13 — — US disclosed
US-20040087661-A1 Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine SEPRACOR, INC. 2004-05-06 — — US disclosed
WO-2004024130-A2 TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE SEPRACOR, INC. (US) 2004-03-25 — — WO disclosed
WO-2004024669-A1 TREATMENT OF CNS DISORDERS WITH TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE AND ITS FORMAMIDE SEPRACOR, INC. (US) 2004-03-25 — — WO disclosed
US-5750794-A Process for preparing chiral tetralone PFIZER INC. (US) 1998-05-12 — — US disclosed
EP-0724552-B1 PROCESS FOR PREPARING A CHIRAL TETRALONE PFIZER (US) 1997-10-29 — — EP disclosed
US-5196607-A Process for preparing ketone enantiomer PFIZER INC. (US) 1993-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180333373-A1 TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE NLN, TPH1, SLC6A3 SLC6A2 13/4885SLC6A4 10/4885SLC6A3 3/4885
US-20210046021-A1 TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE NLN, TPH1, SLC6A3 SLC6A2 13/4885SLC6A4 10/4885SLC6A3 3/4885
US-10702486-B2 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine NLN, TPH1, SLC6A3 SLC6A2 13/4885SLC6A4 10/4885SLC6A3 3/4885
US-10328036-B2 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine NLN, TPH1, SLC6A3 SLC6A2 13/4885SLC6A4 10/4885SLC6A3 3/4885
US-20040092605-A1 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide PNMT, TPH1, NAT1 SLC6A2 6/4885SLC6A4 5/4885SLC6A3 7/4885
US-20040087661-A1 Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine PNMT, HNMT, TPMT SLC6A2 9/4885SLC6A4 7/4885SLC6A3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.